Can you take Cervarix with Inebilizumab?

The human papillomavirus vaccine in Cervarix has a moderate potential interaction with Dehydration.

The administration of human papillomavirus vaccine has been associated with syncope, sometimes resulting in falling with injury. The syncope sometimes is associated with tonic-clonic movements and other seizure-like activity. Caution is recommended when administering the vaccine to individuals susceptible to syncope. Observation for 15 minutes is recommended after its administration.

The human papillomavirus vaccine in Cervarix has a major potential interaction with Fever.

Ideally, vaccination should occur when an individual is healthy, thus minimizing the risk of an adverse host reaction and/or vaccine failure. However, a current or recent infection does not necessarily preclude the use of vaccines, depending on the severity of the patient's symptoms and their etiology. Superficial infections and minor acute illnesses such as a mild upper respiratory infection with or without low-grade fever do not contraindicate immunization, particularly if prompt administration of a vaccine is deemed necessary or beneficial. In fact, when vaccines are administered during the course of a minor illness, the risk of adverse events is not increased, and serum antibody response is not often diminished. On the other hand, if fever or symptoms suggest a moderate or severe illness, it is usually appropriate to withhold vaccination until the patient has recovered. In addition to the potential risks already mentioned, evolving signs and symptoms of the illness can sometimes confound the diagnosis of a vaccine reaction if it develops. In the presence of any infection, the decision to administer or withhold/defer immunization should take into consideration the benefits versus the risks to an individual patient.

The human papillomavirus vaccine in Cervarix has a moderate potential interaction with Hypotension.

The administration of human papillomavirus vaccine has been associated with syncope, sometimes resulting in falling with injury. The syncope sometimes is associated with tonic-clonic movements and other seizure-like activity. Caution is recommended when administering the vaccine to individuals susceptible to syncope. Observation for 15 minutes is recommended after its administration.

The human papillomavirus vaccine in Cervarix has a moderate potential interaction with Immunodeficiency.

The expected serum antibody responses may not be obtained when vaccines and/or toxoids are administered to patients with primary or acquired immunodeficiency, including those with severe combined immunodeficiency, hypogammaglobulinemia or agammaglobulinemia, HIV infection, altered immune states (due to diseases such as leukemia, lymphoma, or generalized malignancy), or immunosuppression due to drug or other treatments (e.g., corticosteroids, alkylating agents, antimetabolites, or radiation).

The human papillomavirus vaccine in Cervarix has a major potential interaction with Infection.

Ideally, vaccination should occur when an individual is healthy, thus minimizing the risk of an adverse host reaction and/or vaccine failure. However, a current or recent infection does not necessarily preclude the use of vaccines, depending on the severity of the patient's symptoms and their etiology. Superficial infections and minor acute illnesses such as a mild upper respiratory infection with or without low-grade fever do not contraindicate immunization, particularly if prompt administration of a vaccine is deemed necessary or beneficial. In fact, when vaccines are administered during the course of a minor illness, the risk of adverse events is not increased, and serum antibody response is not often diminished. On the other hand, if fever or symptoms suggest a moderate or severe illness, it is usually appropriate to withhold vaccination until the patient has recovered. In addition to the potential risks already mentioned, evolving signs and symptoms of the illness can sometimes confound the diagnosis of a vaccine reaction if it develops. In the presence of any infection, the decision to administer or withhold/defer immunization should take into consideration the benefits versus the risks to an individual patient.

Inebilizumab has a moderate potential interaction with Infection.

An increased risk of infections has been observed with the use of inebilizumab. It is recommended to delay administration in patients with an active infection until the infection is resolved. Perform HBV screening in all patients before initiation of treatment. Do not administer this agent to patients with active hepatitis. Patients should be evaluated for tuberculosis risk factors and tested for latent infection prior to initiating treatment. Consider anti-tuberculosis therapy in patients with a history of latent active tuberculosis in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent tuberculosis but having risk factors for tuberculosis infection. Consult infectious disease experts regarding whether initiating therapy is appropriate before starting treatment.

Inebilizumab has a major potential interaction with Infectious Hepatitis.

The use of inebilizumab is contraindicated in patients with active hepatitis B infection.

The human papillomavirus vaccine in Cervarix has a moderate potential interaction with Syncope.

The administration of human papillomavirus vaccine has been associated with syncope, sometimes resulting in falling with injury. The syncope sometimes is associated with tonic-clonic movements and other seizure-like activity. Caution is recommended when administering the vaccine to individuals susceptible to syncope. Observation for 15 minutes is recommended after its administration.

Inebilizumab has a major potential interaction with Tuberculosis, Active.

The use of inebilizumab is contraindicated in patients with active or untreated latent tuberculosis.

Inebilizumab has a major potential interaction with Tuberculosis, Latent.

The use of inebilizumab is contraindicated in patients with active or untreated latent tuberculosis.

Inebilizumab has a moderate potential interaction with Vaccination.

The use of live attenuated-vaccines or live vaccines is not recommended during treatment with inebilizumab until B-cell repletion. Administer all required immunizations at least 4 weeks prior to initiation of inebilizumab. The safety of immunization with live or live-attenuated vaccines following inebilizumab therapy has not been studied, therefore it is not recommended during treatment until B-cell repletion. Do not administer live or live-attenuated vaccines to infants of mothers exposed to inebilizumab during pregnancy before confirming recovery of B-cell counts. Non-live vaccines, may be administered prior to recovery from B-cell and immunoglobulin level depletion, but to assess whether a protective immune response was mounted, consultation with a qualified specialist should be considered.